Are Off-Label Prescriptions of ACE Inhibitors a Promising Therapy for COVID-19? |Biomedgrid

New research published in a leading academic journal shows promise for potentially treating the SARS/COVID-19 virus by targeting angiotensin converting enzymes (ACE). Why don't we speed up the process of therapeutic discovery by exploring whether off-label prescriptions of ACE inhibitors already approved by regulators work in clinic in treating COVID? COVID kills an estimated 13.4% of patients 80 and older, contrasted with 1.25% of those in their 50s and 0.3% of those in their 40s, and is a serious public health threat. Nature Magazine is reporting that COVID-19 binds to the body's angiotensin-converting enzyme, a receptor on human cells [1].